BPMX News

Things just got Seres in the IPO market. Thirteen companies went public this past week, more than any week since October 2014. Seres Therapeutics skyrocketed 186% on its debut - the highest first-day pop since January 2014. The thirteen IPOs raised $1.9 billion, less than expected because 70%...read more

BioPharmX, which is developing therapies for fibrocystic breasts and acne, raised $10 million by offering 3.6 million shares (upsized from 3.3 million shares) at $2.75, the low end of the range of $2.75 to $3.25. Korea Investment Partners Overseas Expansion Platform Fund (KIP) purchased an additional 1.1 million shares at $1.85 per share in a concurrent private placement, bringing...read more

BioPharmX, which is developing therapies for fibrocystic breasts and acne, lowered the proposed deal size for its upcoming IPO on Tuesday. It also disclosed financial results for the three months ended April 30, 2015. The Menlo Park, CA-based company now plans to raise $10 million by offering 3.3 million shares at a price range of $2.75 to $3.25. The company had previously...read more

BioPharmX, which is developing therapies for fibrocystic breasts and acne, announced terms for its public offering on Monday. The Menlo Park, CA-based company plans to raise $17 million by offering 5 million shares at $3.45, its current price on the OTCQB exchange. The company trades under the symbol BPMX with low liquidity. At $3.45, BioPharmX would command a fully diluted...read more